{"id":"https://openalex.org/W2797129642","doi":"https://doi.org/10.1021/acschemneuro.8b00096","title":"New Dopamine D2 Receptor Agonist, [3H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo","display_name":"New Dopamine D2 Receptor Agonist, [3H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo","publication_year":2018,"publication_date":"2018-04-11","ids":{"openalex":"https://openalex.org/W2797129642","doi":"https://doi.org/10.1021/acschemneuro.8b00096","mag":"2797129642","pmid":"https://pubmed.ncbi.nlm.nih.gov/29641175","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8412031"},"language":"en","primary_location":{"id":"doi:10.1021/acschemneuro.8b00096","doi":"https://doi.org/10.1021/acschemneuro.8b00096","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acschemneuro.8b00096","pdf_url":null,"source":{"id":"https://openalex.org/S180465690","display_name":"ACS Chemical Neuroscience","issn_l":"1948-7193","issn":["1948-7193"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Chemical Neuroscience","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8412031","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024728856","display_name":"Sivan Subburaju","orcid":"https://orcid.org/0000-0003-3111-9859","observed_orcids":["https://orcid.org/0000-0003-3111-9859"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sivan Subburaju","raw_affiliation_strings":["Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States"],"raw_orcid":"https://orcid.org/0000-0003-3111-9859","affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States","institution_ids":["https://openalex.org/I2801148111"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077880580","display_name":"Anna W. Sromek","orcid":"https://orcid.org/0000-0001-9753-5797","observed_orcids":["https://orcid.org/0000-0001-9753-5797"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna W. Sromek","raw_affiliation_strings":["Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States","institution_ids":["https://openalex.org/I2801148111"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005802064","display_name":"Philip M. Seeman","orcid":"https://orcid.org/0000-0002-6947-1236","observed_orcids":["https://orcid.org/0000-0002-6947-1236"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Philip Seeman","raw_affiliation_strings":["Departments of Pharmacology and Psychiatry, University of Toronto, 260 Heath St. West, unit 605, Toronto, Ontario Canada M5P 3L6"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Pharmacology and Psychiatry, University of Toronto, 260 Heath St. West, unit 605, Toronto, Ontario Canada M5P 3L6","institution_ids":["https://openalex.org/I185261750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085302392","display_name":"John L. Neumeyer","orcid":"https://orcid.org/0000-0003-2287-9864","observed_orcids":["https://orcid.org/0000-0003-2287-9864"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John L. Neumeyer","raw_affiliation_strings":["Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, United States","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States","institution_ids":["https://openalex.org/I2801148111"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5024728856"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I2801148111"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.3556,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.53672454,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"9","issue":"6","first_page":"1283","last_page":"1289"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.8101000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.8101000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.16439999639987946,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.8610000014305115},{"id":"https://openalex.org/keywords/radioligand-synthesis","display_name":"radioligand synthesis","score":0.8970000147819519},{"id":"https://openalex.org/keywords/raclopride","display_name":"raclopride","score":0.9919999837875366},{"id":"https://openalex.org/keywords/guanylylimidodiphosphate","display_name":"guanylylimidodiphosphate","score":0.878000020980835},{"id":"https://openalex.org/keywords/receptor-binding-affinity","display_name":"receptor binding affinity","score":0.42800000309944153},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.593999981880188},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.949999988079071},{"id":"https://openalex.org/keywords/in-vivo-receptor-imaging","display_name":"in vivo receptor imaging","score":0.7950000166893005}],"concepts":[{"id":"https://openalex.org/C2781069445","wikidata":"https://www.wikidata.org/wiki/Q7279814","display_name":"Raclopride","level":4,"score":0.9331222772598267},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7211149334907532},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.720104992389679},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6507302522659302},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5630586743354797},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5373541116714478},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.49062100052833557},{"id":"https://openalex.org/C116569031","wikidata":"https://www.wikidata.org/wiki/Q899107","display_name":"Ligand (biochemistry)","level":3,"score":0.47778233885765076},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.42091524600982666},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.3888009190559387},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3321493864059448},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3245171308517456},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.288662314414978},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2428058683872223},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.08716446161270142},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001058","descriptor_name":"Apomorphine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D001058","descriptor_name":"Apomorphine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001058","descriptor_name":"Apomorphine","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D017448","descriptor_name":"Receptors, Dopamine D2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D020891","descriptor_name":"Raclopride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1021/acschemneuro.8b00096","doi":"https://doi.org/10.1021/acschemneuro.8b00096","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acschemneuro.8b00096","pdf_url":null,"source":{"id":"https://openalex.org/S180465690","display_name":"ACS Chemical Neuroscience","issn_l":"1948-7193","issn":["1948-7193"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS Chemical Neuroscience","raw_type":"journal-article"},{"id":"pmid:29641175","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29641175","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACS chemical neuroscience","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8412031","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8412031","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"ACS Chem Neurosci","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:8412031","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8412031","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"ACS Chem Neurosci","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8048999905586243,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[{"id":"https://openalex.org/G1253275786","display_name":null,"funder_award_id":"R44 OD024615","funder_id":"https://openalex.org/F4320337349","funder_display_name":"NIH Office of the Director"},{"id":"https://openalex.org/G202419465","display_name":null,"funder_award_id":"R43-OD020186","funder_id":"https://openalex.org/F4320337349","funder_display_name":"NIH Office of the Director"},{"id":"https://openalex.org/G3048383117","display_name":"Development of a Tritiated Agonist Radioligand for the D2 Receptor","funder_award_id":"1r43od020186-01a1","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G3549893021","display_name":"F_18 Labeled D2 Agonist Ligands for PET Imaging of Dopaminergic Dysfunction","funder_award_id":"R21MH103718","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G6284374292","display_name":"Preclinical Validation of Novel High Affinity D2 Receptor Agonists for PET Neuroimaging","funder_award_id":"R44OD024615","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"},{"id":"https://openalex.org/F4320337349","display_name":"NIH Office of the Director","ror":"https://ror.org/00fj8a872"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W305998940","https://openalex.org/W1502799818","https://openalex.org/W1542833865","https://openalex.org/W1546116904","https://openalex.org/W1736549960","https://openalex.org/W1817176777","https://openalex.org/W1964875492","https://openalex.org/W1965820751","https://openalex.org/W1966092598","https://openalex.org/W1969866636","https://openalex.org/W1972278987","https://openalex.org/W1980277133","https://openalex.org/W1992991774","https://openalex.org/W1993345015","https://openalex.org/W1995507480","https://openalex.org/W1999006267","https://openalex.org/W2001859804","https://openalex.org/W2002175275","https://openalex.org/W2006240551","https://openalex.org/W2012810664","https://openalex.org/W2023572775","https://openalex.org/W2027698033","https://openalex.org/W2038536407","https://openalex.org/W2038626564","https://openalex.org/W2044372141","https://openalex.org/W2044621390","https://openalex.org/W2048246008","https://openalex.org/W2048937194","https://openalex.org/W2052746514","https://openalex.org/W2053173214","https://openalex.org/W2058554370","https://openalex.org/W2066278769","https://openalex.org/W2074631079","https://openalex.org/W2077760177","https://openalex.org/W2078606322","https://openalex.org/W2079128738","https://openalex.org/W2083323215","https://openalex.org/W2113742168","https://openalex.org/W2116120834","https://openalex.org/W2117232596","https://openalex.org/W2127893855","https://openalex.org/W2137034059","https://openalex.org/W2151089171","https://openalex.org/W2164955505","https://openalex.org/W2165387697","https://openalex.org/W2168954492","https://openalex.org/W2327661313","https://openalex.org/W2406823737","https://openalex.org/W2554972700","https://openalex.org/W2771312551"],"related_works":["https://openalex.org/W7161991255","https://openalex.org/W3154969302","https://openalex.org/W2096588188","https://openalex.org/W2088578739","https://openalex.org/W1980683756","https://openalex.org/W7099953704","https://openalex.org/W4389008357","https://openalex.org/W2074117907","https://openalex.org/W4409680502","https://openalex.org/W2053445747"],"abstract_inverted_index":{"Increases":[0],"in":[1,25,53,65,164,169],"the":[2,18,29,40,54,71,100],"D2":[3,102],"receptor":[4],"high":[5,105],"affinity":[6],"state":[7],"are":[8],"associated":[9],"with":[10,140],"certain":[11],"neurological":[12],"disorders.":[13],"We":[14],"synthesized":[15],"and":[16,39,77,90,106,130,157,159,166],"characterized":[17],"high-affinity":[19],"D2high":[20,162],"ligand":[21],"[":[22,48,91,109],"3":[23,49,92,110],"H]MCL-536":[24,50,111],"competition":[26,120],"binding":[27,46,64,98,143],"against":[28],"D2/3":[30,41],"agonist":[31],"R":[32],"-(\u2212)-":[33],"N":[34],"-":[35],"n":[36],"-propylnorapomorphine":[37],"(NPA)":[38],"antagonist":[42],"raclopride.":[43],"The":[44,81,94],"total":[45,101],"of":[47,56,116,127,136],"(minus":[51],"that":[52],"presence":[55],"100":[57],"nM":[58],"NPA)":[59],"was":[60],"measured":[61],"by":[62],"saturation":[63],"CHO":[66],"cells":[67],"expressing":[68],"human":[69],"D2long;":[70],"data":[72],"yielded":[73],"separable,":[74],"nonsaturable":[75],"nonspecific,":[76],"saturable":[78],"specific":[79,97],"components.":[80],"former":[82],"represents":[83],"an":[84],"aporphine":[85],"site":[86],"common":[87],"to":[88,99,144],"NPA":[89,122],"H]MCL-536.":[93],"latter":[95],"indicated":[96],"receptors":[103],"(both":[104],"low-affinity":[107],"states).":[108],"had":[112,123,132],"a":[113,124,133,152],"K":[114,125,134],"d":[115],"0.8":[117],"nM.":[118,138],"In":[119],"binding,":[121],"i":[126,135],"0.16":[128],"nM,":[129],"raclopride":[131],"0.9":[137],"Co-incubation":[139],"guanylylimidodiphosphate":[141],"abolished":[142],"D2high.":[145],"This":[146],"unique":[147],"profile":[148],"makes":[149],"radiolabeled":[150],"MCL-536":[151],"versatile":[153],"tool":[154],"for":[155],"diagnostics":[156],"therapeutics,":[158],"may":[160],"quantify":[161],"sites":[163],"schizophrenia":[165],"PD":[167],"patients":[168],"vivo.":[170]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-04-24T00:00:00"}